A Mix-and-Read Cell-Based Assay for Antibody Screening Against Epidermal Growth Factor Receptor
Poster Jul 05, 2011
Wayne Bowen, David Onley, Tristan Cope
The conventional antibody screening assay based on antibody-antigen binding has been enzyme-linked immunosorbent assay (ELISA). While tedious and consuming, ELISA has proved sufficient for the identification of antibodies directed against secreted antigens. However, cell surface antigens (e.g. GPCRs) provide challenges for ELISA due to the shortage of soluble antigens and high variability resulting from loss of cells during wash procedures. Mix-and-read assays (FMAT® assays) overcome such problems.
High Throughput Rheological Characterization of Small Volume Biopharmaceutical FormulationsPoster
Importance of assessing viscosity fingerprints of small molecules.READ MORE
Applications of chemically modified synthetic guide RNA for CRISPR-Cas9 genome editingPoster
Our results indicate that MS modifications are required for experiments with co-electroporation of Cas9 mRNA and synthetic gRNA, yet have no impact on editing efficiency when delivered with lipid-based transfection reagents.READ MORE
Inecalcitol Stimulates CD38 Expression in Multiple Myeloma and Acute Myeloid Leukemia Cell LinesPoster
Inecalcitol is a vitamin D receptor agonist currently in Phase II clinical trial in AML (acute myeloid leukemia). Inecalcitol increases the expression of CD38 at the surface of 5 multiple myeloma cell lines; therefore, inecalcitol could potentiate the clinical response of MM patients to a therapeutic anti-CD38 antibody
Inecalcitol induces the expression of the CD38 antigen at the surface of 4 AML cell lines; thus, inecalcitol could render AML patients sensitive to a therapeutic anti-CD38.